RNLXY · Renalytix plc · Financials
$3.58
+0.03 (+0.70%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 19, 2024
Substantial doubt about the company's ability to continue as a going concern.
“As a result of the Company's losses and its projected cash needs, as defined in the accounting literature, substantial doubt exists about the Company's ability to continue as a going concern. While subsequent to September 30, 2024, the company has successfully raised approximately $14.9 million, net of expenses, in new equity capital and restructured the existing long-term debt recorded on the balance sheet, the Company does have a history of operating losses and it has been expensive to deliver all of the milestones to commercialize the kidneyintelX.dkd test. … As such, management has concluded that there is a going concern uncertainty. The consolidated financial statements do not include any adjustments that may result from the outcome of this going concern uncertainty.”View the 10-Q filed Nov 19, 2024
Market Cap
$47.43M
Shares
13.25M
Volume · Oct 20
3200
Avg daily vol (3M)
7239
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$2.29M
-32.7%
FY2024
Net Income
-$33.46M
+26.6%
FY2024
Gross Margin
6.82%
-14.3pp
FY2024
Operating Margin
-1293.49%
-52.8pp
FY2024
Diluted EPS
-$7.75
+43.6%
FY2024
Operating Cash Flow
-$30.11M
+11.7%
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| $2.35M | $2.29M | $3.4M | $2.97M | $1.49M | $0 | — | |
| $2.05M | $2.13M | $2.68M | $2.1M | $858K | $0 | — | |
| $299K | $156K | $720K | $874K | $633K | $0 | — | |
| — | 6.82% | 21.16% | 29.43% | 42.45% | — | — | |
| $7.42M | $9.29M | $14.3M | $14.65M | $10.04M | $4.57M | $4.32M | |
| $16.96M | $19.75M | $28.66M | $39.52M | $23.48M | $5.75M | $2.74M | |
| $297K | $364K | $508K | $489K | $282K | $70K | $31K | |
| $25.11M | $29.76M | $42.94M | $54.06M | $32.55M | $10.32M | $42.34M | |
| -$24.81M | -$29.61M | -$42.22M | -$53.18M | -$31.92M | -$10.32M | -$42.34M | |
| — | -1293.49% | -1240.7% | -1790.67% | -2140.58% | — | — | |
| -$24.52M | -$29.24M | -$41.71M | -$52.69M | -$31.63M | -$10.25M | -$42.31M | |
| $144K | $249K | $656K | — | $726K | $289K | $18K | |
| — | $0 | -$9000 | $9000 | -$2.11M | -$63K | — | |
| -$28.02M | -$33.45M | -$45.61M | -$45.25M | -$35.34M | -$9.84M | -$42.3M | |
| $6000 | $4000 | $2000 | $25K | $0 | $0 | — | |
| -$28.03M | -$33.46M | -$45.61M | -$45.28M | -$35.34M | -$9.84M | -$42.3M | |
| — | -1461.6% | -1340.2% | -1524.44% | -2369.95% | — | — | |
| — | — | — | $0 | $611K | $0 | — | |
| — | — | — | -$45.28M | -$34.73M | -$9.84M | -$42.3M | |
| — | — | — | -$54.47M | -$25.76M | -$10.22M | -$43.13M | |
| USD/shares | -$6.00 | -$7.75 | -$13.75 | -$15.50 | -$12.25 | -$4.25 | — |
| USD/shares | -$6.00 | -$7.75 | -$13.75 | -$16.75 | -$12.25 | -$4.25 | — |
| shares | — | 4.33M | 3.29M | 2.91M | 2.86M | 2.36M | 1.7M |
| shares | — | 4.33M | 3.29M | 2.95M | 2.86M | 2.36M | 1.7M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of convertible notes payable | 2024-09-30 | USD 4,142,000 | 10-Q filed 2024-11-19 |
| Noncurrent convertible notes payable | 2024-09-30 | USD 4,100,000 | 10-Q filed 2024-11-19 |
| Operating lease liabilities | 2024-09-30 | USD 11,500 | 10-Q filed 2024-11-19 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.